Misdiagnosed chronic pelvic pain: Pudendal neuralgia responding to a novel use of palmitoylethanolamide

Pain Medicine

Volumn 11, Issue 5, 2010, Pages 781-784

  Calabrò, Rocco Salvatore ^a   Gervasi, Giuseppe ^a   Marino, Silvia ^a   Mondo, Pasquale Natale ^a   Bramanti, Placido ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Chronic Pain; PEA; Pudendal Neuralgia

Indexed keywords

PALMIDROL; PREGABALIN; SEX HORMONE; ANALGESIC AGENT; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; PALMITIC ACID DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CHRONIC PAIN; DIAGNOSTIC ERROR; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; EVOKED SOMATOSENSORY RESPONSE; HEALTH CARE PERSONNEL; HORMONE BLOOD LEVEL; HUMAN; HYPERESTHESIA; MALE; MAST CELL; NERVE COMPRESSION; NEURALGIA; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PELVIS FLOOR; PELVIS PAIN SYNDROME; PHYSICAL EXAMINATION; PUDENDAL NERVE; SEMEN ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; URINALYSIS; VISUAL ANALOG SCALE; ANIMAL; COMPLICATION; INNERVATION; NERVE COMPRESSION SYNDROMES; PATHOPHYSIOLOGY; PELVIC PAIN; PERINEUM; TREATMENT OUTCOME;

ADULT; ANALGESICS; ANIMALS; DIAGNOSTIC ERRORS; ENDOCANNABINOIDS; ETHANOLAMINES; HUMANS; MALE; NERVE COMPRESSION SYNDROMES; NEURALGIA; PALMITIC ACIDS; PELVIC PAIN; PERINEUM; TREATMENT OUTCOME;

EID: 77953720756     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00823.x     Document Type: Article

References (14)

1. Labat JJ, Riant T, Robert R. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn 2008, 27(4):306-10.
2. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of endogenous of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-81.
3. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: Evidence for new players. AAPS J 2006, 8:E298-306.
4. Yarnitsky D, Sprecher E, Vardi Y. Penile thermal sensation. J Urol 1996, 156:391-3. 2 Pt 1
5. Lefaucheur JP, Labat JJ, Amarenco G. What is the place of electroneuromyographic studies in the diagnosis and management of pudendal neuralgia related to entrapment syndrome? Neurophysiol Clin 2007, 37(4):223-8.
6. Popeney C, Ansell V, Renney K. Pudendal entrapment as an etiology of chronic perineal pain: Diagnosis and treatment. Neurourol Urodyn 2007, 26(6):820-7. Erratum in: Neurourol Urodyn 2008;27(4):360
7. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993, 39:C145-7. Spec No
8. Calignano A, la Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-81.
9. Jaggar SI, Hasnie FS, Sellaturay S, Rice AC. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998, 76:189-99.
10. Petrosino S, Palazzo E, de Novellis V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007, 52(2):415-22.
11. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: Involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008, 139:541-50.
12. Darmani NA, Izzo AA, Degenhardt B. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology 2005, 48(8):1154-63.
13. Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 2002, 97:11-21.
14. Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 2001, 133(8):1263-75.